Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Top Page
Enlivex
(NASDAQ:ENLV)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.89
▼(-6.21% Downside)
Action:ReiteratedDate:03/28/26
The score is held down primarily by weak financial performance (minimal revenue, persistent operating losses, and ongoing cash burn) despite low leverage. Technical indicators are broadly neutral with slight near-term weakness. Valuation looks optically cheap due to an extremely low P/E, but the quality and sustainability of earnings appear questionable given the lack of operating improvement.
Positive Factors
Late-stage regulatory progress
FDA IND clearance to run a global, randomized, placebo-controlled Phase 2b trial materially advances Allocetra from early proof-of-concept toward definitive efficacy data. This regulatory milestone reduces development pathway uncertainty, improves ability to attract partners, and strengthens long-term commercial potential in a large, aging OA market.
Negative Factors
No recurring commercial revenue
The company lacks recurring product sales and has effectively no revenue across multiple years, meaning core operations aren't self‑funding. Long‑term commercial viability hinges on successful late‑stage trials and commercialization or partner deals, leaving sustained business performance conditional on future clinical outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage regulatory progress
FDA IND clearance to run a global, randomized, placebo-controlled Phase 2b trial materially advances Allocetra from early proof-of-concept toward definitive efficacy data. This regulatory milestone reduces development pathway uncertainty, improves ability to attract partners, and strengthens long-term commercial potential in a large, aging OA market.
Read all positive factors
Enlivex (ENLV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$225.99M
Dividend YieldN/A
Average Volume (3M)182.02K
Price to Earnings (P/E)<0.1
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth46.09%
CountryUS
Employees71
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding237,381,500
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-65.57
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$13.00Price Target Upside1268.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Enlivex Business Overview & Revenue Model
Company Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical tria...
How the Company Makes Money
As a clinical-stage biotechnology company, Enlivex has not been characterized by recurring product sales in its public filings and communications; its operations are typically funded through external financing and other non-commercial sources rath...
Enlivex Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -332.00K | -545.00K | -835.00K | -777.00K | -546.00K |
| EBITDA | -14.67M | -14.47M | -28.22M | -25.02M | -18.74M |
| Net Income | 1.24B | -15.01M | -29.07M | -31.06M | -14.47M |
Balance Sheet | |||||
| Total Assets | 2.33B | 27.69M | 36.83M | 67.64M | 95.15M |
| Cash, Cash Equivalents and Short-Term Investments | 5.87M | 23.61M | 27.32M | 48.12M | 84.13M |
| Total Debt | 641.00K | 534.00K | 1.03M | 4.85M | 617.00K |
| Total Liabilities | 392.05M | 4.10M | 6.75M | 10.80M | 10.11M |
| Stockholders Equity | 1.93B | 23.59M | 30.08M | 56.84M | 85.04M |
Cash Flow | |||||
| Free Cash Flow | -10.48M | -13.11M | -23.76M | -32.08M | -19.17M |
| Operating Cash Flow | -10.42M | -13.01M | -23.52M | -23.95M | -17.54M |
| Investing Cash Flow | -1.32M | 9.06M | -25.97M | 62.52M | -38.41M |
| Financing Cash Flow | 10.38M | 6.45M | 360.00K | 150.00K | 60.98M |
Enlivex Technical Analysis
Negative
0.95
Price Trends
1.09
Negative
1.01
Negative
1.09
Negative
Market Momentum
-0.03
Positive
41.26
Neutral
16.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Negative. The current price of 0.95 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.09, and below the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 41.26 is Neutral, neither overbought nor oversold. The STOCH value of 16.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENLV.
Enlivex Risk Analysis
Enlivex disclosed 70 risk factors in its most recent earnings report. Enlivex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enlivex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $225.99M | 0.03 | -62.91% | ― | ― | 46.09% | |
48 Neutral | $25.33M | -16.10 | 274.47% | ― | ― | ― | |
46 Neutral | $25.92M | -0.82 | -87.18% | ― | ― | 38.42% | |
42 Neutral | $5.06M | -0.56 | -68.21% | ― | ― | ― |
* Healthcare Sector Average
ENLV
Enlivex
0.95
0.06
6.97%
DARE
Daré Bioscience
1.74
-1.14
-39.58%
AKTX
Akari Therapeutics
4.47
-41.93
-90.37%
PASG
Passage Bio
8.08
1.08
15.43%
Enlivex Corporate Events
Enlivex Highlights Rain’s AI Agent Launch and $5 Million Grant Program to Expand Prediction Markets
Mar 26, 2026
On March 26, 2026, Enlivex reported that the Rain Foundation, which oversees the decentralized Rain prediction markets protocol in which Enlivex holds a significant RAIN token position, launched an AI agent‑ready interface and a $5 million g...
Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains
Mar 25, 2026
Enlivex Ltd., a quality longevity company listed on Nasdaq and headquartered in Nes‑Ziona, Israel, combines development of its Allocetra™ immunotherapy for age‑related inflammatory conditions with a treasury strategy tied to the ...
Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback
Mar 24, 2026
On March 23, 2026, Enlivex completed a $21 million senior secured convertible note financing with The Lind Partners, yielding about $18.7 million in net proceeds and convertible into ordinary shares at $2.69175, a hefty premium to its recent Nasda...
Enlivex Wins FDA IND Clearance for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis
Mar 23, 2026
On March 23, 2026, Enlivex announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for Allocetra to treat moderate-to-severe age-related primary knee osteoarthritis. The clearance, based on encouraging...
Enlivex Rebrands as Enlivex Ltd. Following Shareholder Approval
Feb 23, 2026
On February 3, 2026, Enlivex Therapeutics Ltd. held an Extraordinary General Meeting of Shareholders in Israel, where investors approved a proposal to change the company’s name to Enlivex Ltd. The change underscores a streamlining of the cor...
Enlivex’s RAIN Treasury Token Debuts on Kraken to Boost Liquidity
Feb 10, 2026
On February 10, 2026, Enlivex Therapeutics reported that its primary treasury asset, the RAIN token, was listed on the Kraken cryptocurrency exchange effective February 9, 2026. Kraken, one of the most established and liquid U.S.-based digital ass...
Enlivex Shareholders Approve Amended Articles of Association at February 3 Meeting
Feb 5, 2026
On February 3, 2026, Enlivex Therapeutics Ltd. held an Extraordinary General Meeting of Shareholders at which investors approved, by the required majorities, all proposals presented, including a series of amendments to the company’s Articles...
Enlivex Lists RAIN Treasury Token on WhiteBIT to Boost Liquidity
Jan 26, 2026
On January 26, 2026, Enlivex announced that its primary digital treasury asset, the RAIN token, was listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026, giving the token access to a major European and global trading venue. Th...
Enlivex to Delist from Tel Aviv and Shift Trading Exclusively to Nasdaq
Jan 23, 2026
On January 23, 2026, Enlivex Therapeutics announced it has begun the process of voluntarily delisting its ordinary shares from the Tel Aviv Stock Exchange, with trading on the TASE expected to end on April 23, 2026 and the delisting to become effe...
Enlivex Lists RAIN Treasury Token on KuCoin to Deepen Liquidity and Market Access
Jan 7, 2026
On January 7, 2026, Enlivex Therapeutics announced that its primary digital treasury asset, the RAIN token, began trading on the KuCoin cryptocurrency exchange effective January 6, 2026, providing access to one of the world’s largest digital...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.